Bristol-Myers Squibb Co 2025 Sustainability Report
The report highlights BMS's 2025 expansion of medicine access, with ASPIRE reaching 139,700 patients in low- and middle-income countries. It describes a comprehensive double materiality assessment considering societal, environmental and financial impacts. Environmental priorities include a 54.6% absolute emissions reduction goal for Scope 1, Scope 2 and fuel- and energy-related Scope 3 emissions, alongside freshwater and net-zero commitments.
Company: Bristol-Myers Squibb Co
Sector: Manufacturing
Country: United States
Year: 2025
Type: Sustainability Report
Pages: 115
Back to company
Bristol-Myers Squibb Co
Impact Report
The report highlights BMS's 2025 expansion of medicine access, with ASPIRE reaching 139,700 patients in low- and middle-income countries. It describes a comprehensive double materiality assessment considering societal, environmental and financial impacts. Environmental priorities include a 54.6% absolute emissions reduction goal for Scope 1, Scope 2 and fuel- and energy-related Scope 3 emissions, alongside freshwater and net-zero commitments.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Workplace Fatalities
Net Zero Target
Employees